A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
Despite years of active research, there are still no approved medications for the treatment of cocaine dependence. Modafinil is a glutamate-enhancing agent that blunts cocaine euphoria under controlled conditions, and the current study assessed whether modafinil would improve clinical outcome in cocaine-dependent patients receiving standardized psychosocial treatment. This was a randomized, double-blind, placebo-controlled trial conducted at a university outpatient center (from 2002 to 2003) on a consecutive sample of 62 (predominantly African American) cocaine-dependent patients (aged 25-63) free of significant medical and psychiatric conditions. After screening, eligible patients were randomized to a single morning dose of modafinil (400 mg), or matching placebo tablets, for 8 weeks while receiving manual-guided, twice-weekly cognitive behavioral therapy. The primary efficacy measure was cocaine abstinence based on urine benzoylecgonine levels. Secondary measures were craving, cocaine withdrawal, retention, and adverse events. Modafinil-treated patients provided significantly more BE-negative urine samples (p=0.03) over the 8-week trial when compared to placebos, and were more likely to achieve a protracted period (> or =3 weeks) of cocaine abstinence (p=0.05). There were no serious adverse events, and none of the patients failed to complete the study as a result of adverse events. This study provides preliminary evidence, which should be confirmed by a larger study, that modafinil improves clinical outcome when combined with psychosocial treatment for cocaine dependence.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with severe chronic health concerns tend to have a slower response to treatment with fewer days abstinent compared to patients without them.225”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [225]
In the citing paper
“A randomized placebo-controlled trial of modafinil (400mg/d) for CUD indicated significantly lower use compared to placebo, but no significant differences in craving or withdrawal (56), while a larger subsequent trial showed no differences in cocaine use, craving, withdrawal, retention, or abstinence even when accounting for dosage (57).”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [56]
In the citing paper
“Significantly greater abstinence compared to placebo, but no significant differences in craving or withdrawal.”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Dackis et al., 2005
In the citing paper
“Significantly greater abstinence compared to placebo, but no significant differences in craving or withdrawal.”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Dackis et al., 2005
In the citing paper
“Significantly greater abstinence compared to placebo, but no significant differences in craving or withdrawal.”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Dackis et al., 2005
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
(2001) · Statistics for Psychologists · doi:10.4324/9781410605542-11 · Cited by 6,877
The measurement of pessimism: the hopelessness scale
Beck, A. T., Weissman, A., Lester, D., & Trexler, L. (1974) · Journal of Consulting and Clinical Psychology · doi:10.1037/h0037562 · Cited by 5,494 · cited 3×
“…were assessed with the Addiction Severity Index (ASI) (McLellan et al, 1992), Hamilton Anxiety Scale (Ham A) (Hamilton, 1969), and Hamilton Depression Scale (Ham D) (Hamilton, 1967), Beck Depression Inventory (BDI) (Beck et al, 1974), and the Symptom Checklist 90 Revised (SCL90) (Derogatis, 1977).”
MethodThe fifth edition of the addiction severity index
McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,222
Self-citationSobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Diggle, P. J., Heagerty, P. J., Liang, K.-Y., & Zeger, S. L. (2002) · doi:10.1093/oso/9780198524847.001.0001 · Cited by 3,384
Sheehan, D., Lecrubier, Y., Harnett Sheehan, K., Janavs, J., Weiller, E., Keskiner, A., Schinka, J., Knapp, E., Sheehan, M., & Dunbar, G. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83297-x · Cited by 2,149
[Drug addiction and drug abuse].
Feuerlein, W. (1969) · PubMed · Cited by 1,415
Research works printed but not linked: 4
- First MB, Spitzer RL, Gibbon M, Williams JBW (1996). Structured Clinical Interview for DSM-IV Axis I Disorders—Subject Edition (SCID-I/P, Version 2.0). Biometrics Research Department New York State Psychiatric Institute: New York.
- Kadden R, Carroll K, Donovan D, Cooney N, Monti P, Abrams D et al (1992). Cognitive-Behavioral Coping Skills Therapy Manual. US Government Printing Office: Washington, DC.
- Malcolm RJ, Donovan JL, DeVane CL, Elkashef A, Chiang N, Mojsiak J (2002). Influence of Modafinil, 400 or 800 mg/day on Subjective Effects of Intravenous Cocaine in Non-treatment Seeking Volunteers. College on Problems of Drug Dependence: Quebec City.
- Somoza E, Dyrenforth S, Goldsmith J, Mezinskis J, Cohen M (1995). In search of a Universal Drug Craving Scale. Annual Meeting of the American Psychiatric Association: Miami, FL.
Cited by
Drug Addiction as a Pathology of Staged Neuroplasticity
Kalivas, P. W., & O'Brien, C. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301564 · Cited by 733
“Also, modafinil and Nacetylcysteine acting to increase extracellular glutamate and thereby stimulating mGluR-induced inhibition of synaptic glutamate release have shown efficacy in cocaine relapse or cue-induced craving, respectively (Dackis et al, 2005; LaRowe et al, 2007).”
BackgroundSelf-citationModafinil: a review of neurochemical actions and effects on cognition
Minzenberg, M. J., & Carter, C. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301534 · Cited by 713
Scofield, M. D., Heinsbroek, J. A., Gipson, C. D., Kupchik, Y. M., Spencer, S., Smith, A. C. W., Roberts-Wolfe, D., & Kalivas, P. W. (2016) · Pharmacological Reviews · doi:10.1124/pr.116.012484 · Cited by 598
“(Dackis et al., 2005) that failed to replicate in a later trial (Dackis et al.”
ResultVolkow, N. D., Fowler, J. S., Logan, J., Alexoff, D., Zhu, W., Telang, F., Wang, G.-J., Jayne, M., Hooker, J. M., Wong, C., et al. (2009) · JAMA · doi:10.1001/jama.2009.351 · Cited by 529
Glutamatergic substrates of drug addiction and alcoholism
Gass, J. T., & Olive, M. F. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.039 · Cited by 484
“A double-blind placebo-controlled study of treatment-seeking cocaine-dependent outpatients showed that modafinil significantly reduced daily cocaine use and prolonged abstinence [827].”
BackgroundApproved and Investigational Uses of Modafinil: An Evidence-Based Review
Kumar, R. (2008) · Drugs · doi:10.2165/00003495-200868130-00003 · Cited by 415
Anticraving Medications for Relapse Prevention: A Possible New Class of Psychoactive Medications
O’Brien, C. P. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1423 · Cited by 405
“After positive results from an open trial, the results from a randomized, controlled trial were also positive (64), and a multiclinic trial is in progress.”
BackgroundSelf-citationAngarita, G. A., Emadi, N., Hodges, S., & Morgan, P. T. (2016) · Addiction Science & Clinical Practice · doi:10.1186/s13722-016-0056-7 · Cited by 358
“, [12, 63, 64, 176]), its effects on sleep and its pro-cognitive effects position it as the best candidate at present for a viable pharmacotherapy for cocaine use disorders.”
BackgroundThere and Back Again: A Tale of Norepinephrine and Drug Addiction
Weinshenker, D., & Schroeder, J. P. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301263 · Cited by 350
“One recent set of studies reported that the wake-promoting drug, modafinil, which is approved as a treatment for narcolepsy, was able to reduce cocaine intake in a dependent cohort (Dackis et al, 2003; 2005).”
A Systematic Review of Modafinil: Potential Clinical Uses and Mechanisms of Action
Ballon, J. S., & Feifel, D. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0406 · Cited by 349
“However, there were no differences noted between the groups in withdrawal symptoms or long-term cravings.(120) Schizophrenia.”
BackgroundNew medications for drug addiction hiding in glutamatergic neuroplasticity
Kalivas, P. W., & Volkow, N. D. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.46 · Cited by 349
Feil, J., Sheppard, D., Fitzgerald, P. B., Yücel, M., Lubman, D. I., & Bradshaw, J. L. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.03.001 · Cited by 342
“For example, Modafinil, a catecholaminergic agonist, increases extracellular dopamine in the prefrontal cortex, and has been investigated for its applicability in treating cocaine dependence (Anderson et al., 2009; Dackis et al., 2004).”
BackgroundEffect of illicit recreational drugs upon sleep: Cocaine, ecstasy and marijuana
Schierenbeck, T., Riemann, D., Berger, M., & Hornyak, M. (2008) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2007.12.004 · Cited by 291
The solute carrier 6 family of transporters
Bröer, S., & Gether, U. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01975.x · Cited by 269
“Accordingly, modafinil might also be a promising therapeutic agent for cocaine addiction (Dackis et al., 2005; Hart et al., 2008; Minzenberg and Carter, 2008).”
BackgroundControversies in translational research: drug self-administration.
Haney, M., & Spealman, R. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1079-x · Cited by 270
“A pilot clinical trial showed that modafinil (400 mg/day) significantly reduced the number of cocaine-positive urines (Dackis et al. 2005), consistent with the laboratory data.”
BackgroundMonoamine transporters and psychostimulant addiction
Howell, L. L., & Kimmel, H. L. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.003 · Cited by 255
“[347] Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O’Brien CP.”
BackgroundSchmidt, H. D., & Pierce, R. C. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05144.x · Cited by 254
The treatment of cocaine use disorder
Kampman, K. M. (2019) · Science Advances · doi:10.1126/sciadv.aax1532 · Cited by 250
Self-citationA Placebo-Controlled Evaluation of Adjunctive Modafinil in the Treatment of Bipolar Depression
Frye, M. A., Grunze, H., Suppes, T., McElroy, S. L., Keck, P. E., Walden, J., Leverich, G. S., Altshuler, L. L., Nakelsky, S., Hwang, S., et al. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06060981 · Cited by 249
Pharmacological approaches to methamphetamine dependence: a focused review
Karila, L., Weinstein, A., Aubin, H., Benyamina, A., Reynaud, M., & Batki, S. L. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03639.x · Cited by 242
Modafinil for the treatment of cocaine dependence
Anderson, A. L., Reid, M. S., Li, S.-H., Holmes, T., Shemanski, L., Slee, A., Smith, E. V., Kahn, R., Chiang, N., Vocci, F., et al. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.04.015 · Cited by 235
“Finally, modafinil was safe and well tolerated in Phase I interaction studies with cocaine (Donovan et al., 2005; Dackis et al., 2003), and in a pilot study on cocaine dependence treatment (n = 62) it was superior to placebo at promoting cocaine abstinence (Dackis et al., 2005).”
BackgroundMethodResultSelf-citationLevin, F. R., Evans, S. M., Brooks, D. J., & Garawi, F. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.07.004 · Cited by 220
Neuroscience of Behavioral and Pharmacological Treatments for Addictions
Potenza, M. N., Sofuoglu, M., Carroll, K. M., & Rounsaville, B. J. (2011) · Neuron · doi:10.1016/j.neuron.2011.02.009 · Cited by 214
Glutamatergic medications for the treatment of drug and behavioral addictions
Olive, M. F., Cleva, R. M., Kalivas, P. W., & Malcolm, R. J. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.015 · Cited by 210
“A double-blind placebo-controlled study of treatmentseeking cocaine-dependent outpatients showed that modafinil (400 mg/day) significantly reduced daily cocaine use and prolonged abstinence (Dackis et al., 2005).”
BackgroundA double-blind, placebo-controlled trial of modafinil for cocaine dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Plebani, J. G., Pettinati, H. M., Sparkman, T., & O'Brien, C. P. (2012) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2011.12.014 · Cited by 187
“GEE Comparisons of Abstinence Rates Since we found poor concordance between patient self-reports and our objective UDS measure of abstinence, which is consistent with our prior experience (Dackis et al., 2005), we focused exclusively on the UDS results.”
BackgroundMethodResultInfluentialSelf-citationEvidence for the Involvement of Dopamine Transporters in Behavioral Stimulant Effects of Modafinil
Zolkowska, D., Jain, R., Rothman, R. B., Partilla, J. S., Roth, B. L., Setola, V., Prisinzano, T. E., & Baumann, M. H. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.146142 · Cited by 184
“Recently, modafinil has been prescribed for other psychiatric disorders such as attentiondeficit hyperactivity disorder (Swanson et al., 2006) and cocaine dependence (Dackis et al., 2005).”
BackgroundRegulation of the dopamine transporter: Aspects relevant to psychostimulant drugs of abuse
Schmitt, K. C., & Reith, M. E. A. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05148.x · Cited by 180
An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: A pilot study
Mardikian, P. N., LaRowe, S. D., Hedden, S., Kalivas, P. W., & Malcolm, R. J. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.10.001 · Cited by 179
“While some medications have shown promise in the treatment of cocaine dependence, including Disulfiram (Caroll et al., 1998), Baclofen (Shoptaw et al., 2003), Topiramate (Kampman et al., 2004), and Modafinil (Dackis et al., 2005), none have received FDA approval.”
BackgroundNew treatments for cocaine dependence: a focused review
Karila, L., Gorelick, D., Weinstein, A., Noble, F., Benyamina, A., Coscas, S., Blecha, L., Lowenstein, W., Martinot, J. L., Reynaud, M., et al. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008097 · Cited by 178
“The first randomized, double-blind clinical trial involved 40 cocaine-dependent outpatientswho received topiramate (up to 200 mg/d) or placebo for 13 wk, in conjunction with twice weekly CBT (Kampman et al., 2004).”
MethodInfluentialSmoked Cocaine Self-Administration is Decreased by Modafinil
Hart, C. L., Haney, M., Vosburg, S. K., Rubin, E., & Foltin, R. W. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301472 · Cited by 174
“…effects of cocaine (eg cocaine craving and the amount participants were willing to pay for the dose sampled) and this is in line with results from previous laboratory studies that have assessed subjective response to cocaine in the presence of modafinil (Dackis et al, 2003; Malcolm et al, 2006).”
InfluentialA double‐blind placebo‐controlled trial of N‐acetylcysteine in the treatment of cocaine dependence
LaRowe, S. D., Kalivas, P. W., Nicholas, J. S., Randall, P. K., Mardikian, P. N., & Malcolm, R. J. (2013) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2013.12034.x · Cited by 164
Medications development: Successes and challenges
Vocci, F., & Ling, W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.010 · Cited by 160
Bentzley, B. S., Han, S. S., Neuner, S., Humphreys, K., Kampman, K. M., & Halpern, C. H. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.8049 · Cited by 161
Self-citationA double‐blind, placebo‐controlled trial of modafinil (200 mg/day) for methamphetamine dependence
Shearer, J., Darke, S., Rodgers, C., Slade, T., Van Beek, I., Lewis, J., Brady, D., McKetin, R., Mattick, R. P., & Wodak, A. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02437.x · Cited by 159
“This finding was consistent with the findings of Dackis and colleagues, who found no reduction in craving in cocaine users measured using a similar visual analogue scale [25].”
BackgroundResultTardelli, V. S., Bisaga, A., Arcadepani, F. B., Gerra, G., Levin, F. R., & Fidalgo, T. M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05563-3 · Cited by 151
The role of neuroadaptations in relapse to drug seeking
Shaham, Y., & Hope, B. T. (2005) · Nature Neuroscience · doi:10.1038/nn1105-1437 · Cited by 171
Treatment Strategies for Co-Occurring ADHD and Substance Use Disorders
Mariani, J. J., & Levin, F. R. (2007) · The American Journal on Addictions · doi:10.1080/10550490601082783 · Cited by 153
Fronto-striatal circuits in response-inhibition: Relevance to addiction
Morein-Zamir, S., & Robbins, T. W. (2015) · Brain Research · doi:10.1016/j.brainres.2014.09.012 · Cited by 153
Ceceli, A. O., Bradberry, C. W., & Goldstein, R. Z. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-021-01153-9 · Cited by 150
Mereu, M., Bonci, A., Newman, A. H., & Tanda, G. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3232-4 · Cited by 148
“…good safety and tolerability use of MOD during the 8 weeks of its administration, providing adverse events in <5 % of subjects, it failed to confirm the previously reported significant differences between MOD and placebo over the same measures/effects of cocaine abstinence (Dackis et al. 2012).”
InfluentialThe role of human drug self-administration procedures in the development of medications
Comer, S. D., Ashworth, J., Foltin, R. W., Johanson, C. E., Zacny, J. P., & WALSH, S. L. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.03.001 · Cited by 155
“These findings are in agreement with a small-scale clinical trial that examined the efficacy of modafinil compared to placebo in individuals seeking treatment for cocaine dependence and reported significant reductions in cocaine use in the group treated with modafinil (Dackis et al., 2005).”
ResultPharmacotherapy for smoking cessation: pharmacological principles and clinical practice
Aubin, H., Luquiens, A., & Berlin, I. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12116 · Cited by 138
Developments in harmine pharmacology — Implications for ayahuasca use and drug-dependence treatment
Brierley, D. I., & Davidson, C. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.001 · Cited by 158
Reith, M. E. A., Blough, B. E., Hong, W. C., Jones, K. T., Schmitt, K. C., Baumann, M. H., Partilla, J. S., Rothman, R. B., & Katz, J. L. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.12.005 · Cited by 136
Self‐administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls
Haney, M. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00121.x · Cited by 134
“…findings correspond well with pilot clinical trial data showing that modafinil significantly reduced the number of cocainepositive urines (Dackis et al. 2005), and with a recent multi-site clinical trial, which appear to confirm modafinil’s efficacy to promote abstinence in…”
ResultEfficacy of Psychostimulant Drugs for Cocaine Dependence
Castells, X., Casas, M., Pérez-Mañá, C., Roncero, C., Vidal, X., & Capellà, D. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007380.pub3 · Cited by 130
Santibanez, S. S., Garfein, R. S., Swartzendruber, A. L., Purcell, D. W., Paxton, L. A., & Greenberg, A. E. (2006) · Journal of Urban Health · doi:10.1007/s11524-005-9009-2 · Cited by 134
“There are no approved medications for cocaine treatment, although modafinil and topiramate are promising.(71,72) There are no approved medications for methamphetamine treatment.”
BackgroundCzoty, P. W., Stoops, W. W., & Rush, C. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011668 · Cited by 145
“In the third trial, 210 subjects were randomized to placebo (n = 75), 200 mg/day modafinil (n = 65), or 400 mg/day modafinil (n = 70) combined with cognitive behavioral therapy for 8 weeks (Dackis et al., 2012).”
BackgroundMethodEvidence-based treatments of addiction
O'Brien, C. P. (2008) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2008.0105 · Cited by 123
Self-citationSchmitt, K. C., & Reith, M. E. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025790 · Cited by 133
Freeman, W. M., Patel, K. M., Brucklacher, R. M., Lull, M. E., Erwin, M. S., Morgan, D., Roberts, D. C. S., & Vrana, K. E. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301577 · Cited by 130
“Previously, we reported that after discrete-trial cocaine self- administration and 10 days of forced abstinence, incubation of cocaine reinforcement was observable by a progressive ratio schedule.”
BackgroundWINSTANLEY, C. A. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1401.024 · Cited by 119
Ghahremani, D. G., Tabibnia, G., Monterosso, J. R., Hellemann, G. S., Poldrack, R. A., & London, E. D. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.233 · Cited by 136
“…825 0606; Fax: + 1 (310) 825 0812, E-mail: darag@ucla.edu or elondon@mednet.ucla.edu with such agents has been observed in the treatment of cocaine (Dackis et al, 2005) and MA dependence (Shearer et al, 2009), but few studies have examined the direct effects of these potential pharmacotherapies on…”
BackgroundNeuroscience of drug craving for addiction medicine
Ekhtiari, H., Nasseri, P., Yavari, F., Mokri, A., & Monterosso, J. R. (2015) · Progress in brain research · doi:10.1016/bs.pbr.2015.10.002 · Cited by 141
Modafinil for the treatment of methamphetamine dependence
Anderson, A. L., Li, S.-H., Biswas, K., McSherry, F., Holmes, T., Iturriaga, E., Kahn, R., Chiang, N., Beresford, T., Campbell, J., et al. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.07.007 · Cited by 117
Cocaine and amphetamine-like psychostimulants: neurocircuitry and glutamate neuroplasticity
Kalivas, P. W. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.4/pkalivas · Cited by 117
“Notably, modafinil has been found to successfully decrease cocaine relapse in a number of clinical trials.(77,78) The primary drugs in the category of nonspecific inhibitors of synaptic glutamate release include a variety of γ-aminobutyric acid (GABA)-mimetic compounds.”
BackgroundNeurobiology of Cocaine Addiction: Implications for New Pharmacotherapy
Kalivas, P. W. (2007) · The American Journal on Addictions · doi:10.1080/10550490601184142 · Cited by 117
“Regardless of the precise mechanisms, recent placebo controlled, double-blind clinical trials indicate that modafinil reduces cocaine craving and rates of cocaine use.(32,33) Based on animal studies, developing glutamatergic drugs that treat cocaine addiction by attenuating glutamate signaling in neurons is a viable a…”
BackgroundMORGAN, P. T., Pace-Schott, E. F., Sahul, Z. H., Coric, V., Stickgold, R., & Malison, R. T. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.09.014 · Cited by 130
Approaches to the development of medications for the treatment of methamphetamine dependence
Vocci, F. J., & Appel, N. M. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01772.x · Cited by 114
Novel pharmacotherapeutic treatments for cocaine addiction
Shorter, D. I., & Kosten, T. R. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-119 · Cited by 119
Neural Substrates of Psychostimulant Withdrawal-Induced Anhedonia
D’Souza, M. S., & Markou, A. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_20 · Cited by 116
“2006), and compounds that enhance glutamatergic function (Dackis et al. 2005).”
BackgroundHeinzerling, K. G., Swanson, A.-N., Kim, S., Cederblom, L., Moe, A., Ling, W., & Shoptaw, S. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.023 · Cited by 105
“Previous clinical studies in cocaine dependence found similar outcomes for modafinil at 400 mg and 200 mg doses (Anderson et al., 2009; Dackis et al., 2005; Hart et al., 2008) while modafinil’s dopaminergic effects in a human imaging study were equivalent for 400 mg and 200 mg doses (Volkow et al.,…”
BackgroundResultTopiramate in the Treatment of Substance-Related Disorders: A Critical Review of the Literature
Shinn, A. K., & Greenfield, S. F. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04062gry · Cited by 103
Zack, M., & Poulos, C. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108091072 · Cited by 103
Animal Models and Brain Circuits in Drug Addiction
Kalivas, P. W., Peters, J., & Knackstedt, L. (2006) · Molecular Interventions · doi:10.1124/mi.6.6.7 · Cited by 103
Cognitive Function as a Transdiagnostic Treatment Target in Stimulant Use Disorders
Sofuoglu, M., DeVito, E. E., Waters, A. J., & Carroll, K. M. (2016) · Journal of Dual Diagnosis · doi:10.1080/15504263.2016.1146383 · Cited by 109
Pharmacotherapy and other treatments for cocaine abuse and dependence
Vocci, F. J., & Elkashef, A. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165596.98552.02 · Cited by 100
Corticolimbic dysregulation and chronic methamphetamine abuse
Baicy, K., & London, E. D. (2007) · Addiction · doi:10.1111/j.1360-0443.2006.01777.x · Cited by 102
Emerging pharmacological strategies in the fight against cocaine addiction
Sofuoglu, M., & Kosten, T. R. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.1.91 · Cited by 102
“Modafinil was recently examined for cocaine pharmacotherapy in 62 cocaine-dependent patients in a double-blind, placebocontrolled trial [73].”
BackgroundFox, H. C., Jackson, E. D., & Sinha, R. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.03.007 · Cited by 115
“Furthermore, glutamatergic agents such as Modafinil, which have been shown to prolong cocaine abstinence (Dackis et al., 2005), also have beneficial effects on both executive control and episodic memory in patients with Major Depression (DeBattista et al.”
BackgroundHerin, D. V., Rush, C. R., & Grabowski, J. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05145.x · Cited by 98
Pettinati, H. M., Kampman, K. M., Lynch, K. G., Xie, H., Dackis, C., Rabinowitz, A. R., & O′Brien, C. P. (2008) · Addictive Behaviors · doi:10.1016/j.addbeh.2007.11.011 · Cited by 95
Self-citationDeveloping neuroscience-based treatments for alcohol addiction: A matter of choice?
Heilig, M. A., Augier, E., Pfarr, S., & Sommer, W. H. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0591-6 · Cited by 107
Medications for substance use disorders
Douaihy, A. B., Kelly, T. M., & Sullivan, C. (2013) · Social Work in Public Health · doi:10.1080/19371918.2013.759031 · Cited by 93
Normalizing Effects of Modafinil on Sleep in Chronic Cocaine Users
Morgan, P. T., Pace-Schott, E., Pittman, B., Stickgold, R., & Malison, R. T. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09050613 · Cited by 93
Dopamine transporter-related effects of modafinil in rhesus monkeys
Andersen, M. L., Kessler, E., Murnane, K. S., McClung, J. C., Tufik, S., & Howell, L. L. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1839-2 · Cited by 98
“A limited number of clinical studies suggest that modafinil may improve clinical outcomes for the treatment of cocaine dependence, reducing self-reports of craving and cocaine-induced euphoria (Dackis et al. 2003, 2005; Hart et al. 2008; Anderson et al. 2009).”
BackgroundKampman, K. M., Lynch, K. G., Pettinati, H. M., Spratt, K., Wierzbicki, M. R., Dackis, C., & O’Brien, C. P. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.08.005 · Cited by 90
“The main difference between this trial and the previous negative trial (Dackis et al. 2012) was medication adherence.”
BackgroundResultInfluentialSelf-citationSwann, A. C. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05146.x · Cited by 109
Kampman, K. M., Dackis, C. A., Lynch, K. G., Pettinati, H. M., Tirado, C. F., Gariti, P., Sparkman, T., Atzram, M., & O’Brien, C. P. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.04.002 · Cited by 95
Self-citationParallel Roles for Dopamine in Pathological Gambling and Psychostimulant Addiction
Zack, M., & Poulos, C. (2009) · Current Drug Abuse Reviewse · doi:10.2174/1874473710902010011 · Cited by 86
“Modafinil is used for the treatment of narcolepsy but has also proven effective in the treatment of ADHD and cocaine addiction [105,106].”
BackgroundModafinil as a Catecholaminergic Agent: Empirical Evidence and Unanswered Questions
Wisor, J. P. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00139 · Cited by 102
“And other clinical trials in humans, in which modafinil has failed to significantly improve abstinence rates during methamphetamine withdrawal (77, 78) or cocaine withdrawal (79), are revealing from both a conceptual standpoint and a practical one.”
BackgroundStoops, W. W., Lile, J. A., Fillmore, M. T., Glaser, P. E. A., & Rush, C. R. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0044-1 · Cited by 85
“Indeed, the results of a recently published small-scale clinical trial suggest that modafinil may be a promising pharmacotherapy for cocaine dependence (Dackis et al. 2005).”
ResultClinical Care of the HIV-Infected Drug User
Bruce, R. D., & Altice, F. L. (2007) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2007.03.009 · Cited by 94
Mariani, J. J., Pavlicova, M., Bisaga, A., Nunes, E. V., Brooks, D. J., & Levin, F. R. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.032 · Cited by 85
McGregor, C., Srisurapanont, M., Mitchell, A., Wickes, W., & White, J. M. (2008) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2007.12.003 · Cited by 82
Cognitive enhancers in the treatment of substance use disorders: Clinical evidence
Brady, K. T., Gray, K. M., & Tolliver, B. K. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.017 · Cited by 82
“…outpatients, Dackis et al. (2005) found no effect of modafinil on study retention or CBT attendance but reported a significantly higher proportion of benzoylecgonine-negative urine drug screens inmodafinil-treated subjects as compared to the placebo-treated group (Dackis et al., 2005).”
BackgroundResultInfluentialBenefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy
Lavault, S., Dauvilliers, Y. A., Drouot, X., Leu‐Semenescu, S., Golmard, J., Lecendreux, M., Franco, P., & Arnulf, I. (2011) · Sleep Medicine · doi:10.1016/j.sleep.2011.03.010 · Cited by 88
“Since the safety of modafinil is excellent, the drug has been approved to alleviate sleepiness and fatigue in several other disorders, including shift work disorders [17] and residual sleepiness in treated sleep apnea syndrome [18,19], and has also been tested for the treatment of multiple sclerosis [20], Parkinson’s…”
BackgroundREVIEW: New developments in the pharmacotherapy of cocaine abuse
Preti, A. (2007) · Addiction Biology · doi:10.1111/j.1369-1600.2007.00061.x · Cited by 79
“…and psychiatric conditions found significantly more negative urine samples over the 8-week trial when compared with placebo, and a higher chance of achieving prolonged cocaine abstinence in the sample, with no serious adverse events and a high retention rate (no dropout) (Dackis et al. 2005).”
BackgroundPsychostimulant Treatment of Cocaine Dependence
Mariani, J. J., & Levin, F. R. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2012.03.012 · Cited by 80
The self‐medication hypothesis and psychostimulant treatment of cocaine dependence: An update
Mariani, J. J., Khantzian, E. J., & Levin, F. R. (2014) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2013.12086.x · Cited by 78
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78
Psychostimulant addiction treatment
Phillips, K. A., Epstein, D. H., & Preston, K. L. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.04.002 · Cited by 75
“However, more recent clinical trials in patients with cocaine-use disorder (Dackis et al., 2012) or methamphetamine-use disorder (Anderson et al.”
BackgroundMethodFischer, B., Blanken, P., da Silveira, D. X., Gallassi, A. D., Goldner, E. M., Rehm, J. T., TYNDALL, M. W., & Wood, E. (2015) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.01.002 · Cited by 101
New horizons for therapeutics in drug and alcohol abuse
Jupp, B., & Lawrence, A. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.002 · Cited by 85
Castells, X., Casas, M., Vidal, X., Bosch, R., Roncero, C., Ramos‐Quiroga, J. A., & Capellà, D. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01943.x · Cited by 74
“Also, the original modafinil study [46] showed a statistically significant beneficial effect on cocaine use.”
Common and distinct neural targets of treatment: Changing brain function in substance addiction
Konova, A. B., Moeller, S. J., & Goldstein, R. Z. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.10.002 · Cited by 73
Modafinil evokes striatal [3H]dopamine release and alters the subjective properties of stimulants
Dopheide, M. M., Morgan, R. E., Rodvelt, K. R., Schachtman, T. R., & Miller, D. K. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.03.044 · Cited by 74
“Moreover, modafinil has recently been considered as a treatment to minimize the withdrawal symptoms from long-term amphetamine or cocaine use (Dackis et al., 2003, 2005).”
BackgroundCocaine Use Disorder (CUD): Current Clinical Perspectives
Schwartz, E. K. C., Wolkowicz, N. R., Aquino, J. P. D., MacLean, R. R., & Sofuoglu, M. (2022) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s337338 · Cited by 102
“However, in a follow-up study, the authors were unable to replicate this effect.(117) A meta-analysis including 11 studies found that overall, modafinil was not superior to placebo in improving measures of CUD, yet the authors noted that in a subgroup analysis of 6 studies conducted in the US, modafinil increased coca…”
ResultRapinesi, C., CASALE, A. D., Pietro, S. D., Ferri, V. R., Piacentino, D., Sani, G., Raccah, R. N., Zangen, A., Ferracuti, S., Vento, A. E., et al. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.06.049 · Cited by 83
Anti-relapse medications: Preclinical models for drug addiction treatment
Yahyavi-Firouz-Abadi, N., & See, R. E. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.014 · Cited by 70
“Modafinil 62 Cocaine dependent ↑ negative urine screen (Dackis et al., 2005)”
BackgroundInfluential
Metadata
- Authors
- Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Dackis, Charles A
- Venue
- Neuropsychopharmacology
- Published
- 2004-11-03
- Volume
- 30
- Issue
- 1
- Pages
- 205-211
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1966136869
- Cited by
- 391
- References
- 44
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 9 · 2021: 13 · 2020: 2 · 2019: 10 · 2018: 6 · 2017: 8 · 2016: 21 · 2015: 17 · 2014: 21 · 2013: 21 · 2012: 26
- FWCI
- 19.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p60da005186-25)
- National Institute on Drug Abuse (DA P60-05186, DA P50-12756, P50DA012756)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- modafinil, cocaine dependence, cocaine abstinence, cognitive behavioral therapy, psychosocial interventions, cocaine craving, cocaine withdrawal, medication-assisted treatment, African American patients
- MeSH terms
- Modafinil, Adult, Central Nervous System Stimulants, Benzhydryl Compounds, Double-Blind Method, Female, Humans, Male, Middle Aged, Patient Compliance, Psychiatric Status Rating Scales, Substance Withdrawal Syndrome, Treatment Outcome, Sample Size, Cocaine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.